Earnings Releases·Nov 5, 2026, 4:35 PM ET

BioAge Labs — Third Quarter 2026 Earnings Summary

Collaboration revenue declined 86% year-over-year to $0.3 million, driven by a $1.7 million cumulative catch-up adjustment from a September 2026 Novartis Agreement amendment, contributing to a net loss of $33.5 million ($0.73 per share) versus $20.2 million in the prior year.
Research and development expenses rose 63% to $30.2 million, primarily due to $13.2 million in higher direct costs for the BGE-102 program and increased personnel expenses, while general and administrative costs increased to $7.5 million.
Clinical progress includes the completion of enrollment for the QUELL-CV Phase 2 trial (160 participants) and the dosing of the first participant in the QUELL-DME Phase 2 trial for BGE-102, with topline data expected in Q4 2026 for QUELL-CV and H2 2027 for QUELL-DME.
Management estimates existing cash and marketable securities of $352.3 million will fund operations through 2029, with plans to file the first IND for the APJ agonist program by year-end 2026.